Stock analysts at Aegis began coverage on shares of Revance Therapeutics Inc. (NASDAQ:RVNC) in a report released on Tuesday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.
RVNC has been the topic of several other reports. Zacks Investment Research lowered shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 17th. Brean Capital reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, August 5th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $36.37.
Revance Therapeutics (NASDAQ:RVNC) opened at 18.15 on Tuesday. Revance Therapeutics has a 52 week low of $12.35 and a 52 week high of $40.40. The company’s market capitalization is $517.55 million. The firm has a 50 day moving average of $15.79 and a 200-day moving average of $15.46.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.25. Revance Therapeutics had a negative net margin of 28,187.33% and a negative return on equity of 37.31%. During the same period last year, the firm earned ($0.81) EPS. On average, analysts forecast that Revance Therapeutics will post ($3.21) earnings per share for the current year.
In other Revance Therapeutics news, CEO L Daniel Browne sold 12,000 shares of the stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $17.92, for a total transaction of $215,040.00. Following the sale, the chief executive officer now directly owns 208,449 shares in the company, valued at $3,735,406.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 31.15% of the company’s stock.
Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in shares of Revance Therapeutics by 9.9% in the second quarter. JPMorgan Chase & Co. now owns 3,327,022 shares of the biopharmaceutical company’s stock worth $45,247,000 after buying an additional 298,448 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Revance Therapeutics by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 2,118,558 shares of the biopharmaceutical company’s stock worth $28,812,000 after buying an additional 152,383 shares during the last quarter. Polar Capital LLP increased its stake in shares of Revance Therapeutics by 13.0% in the third quarter. Polar Capital LLP now owns 1,319,871 shares of the biopharmaceutical company’s stock worth $21,392,000 after buying an additional 151,329 shares during the last quarter. BlackRock Fund Advisors increased its stake in shares of Revance Therapeutics by 10.3% in the third quarter. BlackRock Fund Advisors now owns 1,317,731 shares of the biopharmaceutical company’s stock worth $21,360,000 after buying an additional 123,376 shares during the last quarter. Finally, Iguana Healthcare Management LLC purchased a new stake in shares of Revance Therapeutics during the second quarter worth about $1,360,000.
About Revance Therapeutics
Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.